Le Lézard
Classified in: Health
Subject: PDT

Elekta Introduces Strategy for Precision Radiation Medicine at ASTRO Annual Meeting


SAN ANTONIO, Oct. 19, 2018 /PRNewswire/ -- At the American Society for Radiation Oncology (ASTRO) Annual Meeting, October 21-24 in San Antonio, Elekta (EKTA-B.ST) will introduce MOSAIQ Plaza, Elekta's suite of data-focused integrative oncology software, and highlight the company's comprehensive strategy for precision radiation medicine. This strategy integrates Elekta's dual commitments to enabling complex radiation therapy treatment regimens while simplifying and streamlining the delivery of care. Elekta Unity*, the company's transformative magnetic resonance radiation therapy (MR/RT) system and MOSAIQ Plaza are the most recent evidence of Elekta's ability to fulfill these commitments.

"We believe that clinicians and patients around the world should have access to life-changing, life-saving care," said Richard Hausmann, President and CEO, Elekta. "Achieving this goal requires advanced radiation therapy solutions. Our focus on precision radiation medicine reflects our commitment to innovating solutions that enable personalized radiation therapy that can rapidly be adapted to changes in tumor size and shape and use intelligent data processing to streamline treatments."

ASTRO attendees are invited to visit Elekta booth #2433 to learn more about how Elekta is using precision radiation medicine to work towards a future where everyone can benefit from precise and individually tailored radiotherapy treatments, including:

-       Elekta SmartClinic: An intuitive game-changer, enabling process visualization and automated streamlined care coordination with fewer clicks and portability, designed by Elekta with clinical partners and made for MOSAIQ®.

-       Monaco® HD treatment planning: the gold standard for delivering fast and accurate treatment plans. With Smart Sequencing and true Multicriterial Optimization, Monaco HD achieves superior plan quality with short delivery time.  

-       IBM Watson for Oncology: A powerful tool that augments clinicians' expertise with evidence-based decision support and provides patients with data-driven care regardless of where they are treated.

-       Voice Automation: A transformative solution that integrates Palabra's cutting-edge voice recognition technology and customizable templates with MOSAIQ, reducing the time needed to create accurate patients notes.

-       Care Collaboration: Supports tumor boards and multidisciplinary meeting experiences with cross-specialty data visualization. 

-       Elekta Unity, the first high field magnetic resonance radiation therapy system, which allows clinicians to see and track difficult-to-visualize soft tissue anatomies during radiation dosing.

-       Leksell Gamma Knife® Icontm, the clear choice for intracranial radiosurgery, offers HD motion management and stereotactic CBCT imaging, allowing for precision radiosurgery with online dose adaptation.

-       Versa HDtm, an HDRS (High definition dynamic radiosurgery) platform that offers precision and speed to deliver SRS and SBRT treatments throughout the body in standard treatment time slots.

-       Elekta brachytherapy solutions, including Veneziatm, a gynecologic brachytherapy applicator designed to treat advanced cervical cancer.

For updates from ASTRO, SROA and ASRT, follow Elekta on Twitter at @Elekta.

To learn more about our events, including the Elekta User Meeting, educational programs and our evening fundraising event supporting the San Antonio-based Alamo Breast Cancer Foundation (ABCF), visit elekta.com/ASTRO.

*Elekta Unity is pending 510(k) premarket clearance and not available for commercial distribution or sale in the U.S.

For further information, please contact:
Oskar Bosson
Global EVP Corporate Communications and Investor Relations
Tel: +46-70-410-7180,
e-mail: [email protected]
Time zone: CET: Central European Time 

Raven Canzeri, Global Public Relations Manager
Tel: +1-770-670-2524,
e-mail: [email protected]
Time zone: ET: Eastern Time

About Elekta

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,700 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/elekta/r/elekta-introduces-strategy-for-precision-radiation-medicine-at-astro-annual-meeting,c2648900

The following files are available for download:

http://mb.cision.com/Main/35/2648900/929283.pdf

PDF

 

 

SOURCE Elekta


These press releases may also interest you

at 12:15
ResBiotic Nutrition, Inc. (ResBiotic), the pioneering physician-developed pre/probiotic wellness scale-up, proudly announces the appointments of Stefany Nieto as Vice President of Operations and Brittany Zenner as Director of Marketing. Nieto is a...

at 12:06
Maid Sailors Cleaning Service has joined forces with Cleaning for a Reason, a non-profit organization offering free house cleaning services to cancer patients across the United States and Canada....

at 12:05
Terragia Biofuel, a technology startup aiming to drive the next generation of biofuels, today announced it has raised a $6 million seed round led by Engine Ventures and Energy Impact Partners (EIP). The company will use the capital to commercialize...

at 12:05
Float, the marketplace moving all the care that doesn't need a hospital to the home, today announced $10 million in Series A funding led by Canvas Ventures, whose General Partner Mike Ghaffary has joined Float's board, with participation from Wave...

at 12:00
V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology's (ACC) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. RELIEVE-HF is a randomized, double-blind,...

at 12:00
Critical Path Institute's (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for...



News published on and distributed by: